Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review
Author:
Burattini Marco1, Falsetti Lorenzo2ORCID, Potente Eleonora1, Rinaldi Claudia1, Bartolini Marco1, Buratti Laura1, Silvestrini Mauro1, Viticchi Giovanna1ORCID
Affiliation:
1. Neurological Clinic , Marche Polytechnic University , via Conca n.1, 60020 , Ancona , Italy 2. Internal and Subintensive Medicine , Ospedali Riuniti Ancona , via Conca n.1, 60020 , Ancona , Italy
Abstract
Abstract
Polycythemia vera (PV) is a myeloproliferative disorder associated with an increased risk of cerebrovascular diseases. In this narrative review, we aimed to analyze the relationships between acute ischemic stroke and PV. We conducted a PubMed/Medline and Web of Sciences Database search using MeSH major terms. We found 75 articles and finally considered 12 case reports and 11 cohort studies. The ischemic stroke resulted as the first manifestation of PV in up to 16.2% of cases; the cumulative rate of cerebrovascular events was up to 5.5 per 100 persons per year and stroke accounted for 8.8% of all PV-related deaths; age, mutations, and a previous history of thrombosis were the main risk factors. The best approach to reduce stroke recurrence risk is unclear, even if some evidence suggests a potential role of lowering hematocrit below 45%. Ischemic stroke represents one of the most common PV manifestations but, despite their relationship, patients with both diseases have a very heterogeneous clinical course and management. PV-related strokes often remain underdiagnosed, especially for the low prevalence of PV. An early diagnosis could lead to prompt treatment with phlebotomy, cytoreduction, and low-dose aspirin to decrease the risk of recurrences. Clinicians should be aware of PV as a risk factor for stroke when approaching the differential diagnosis of cryptogenic strokes. An early diagnosis could positively influence patients’ management and clinical outcomes. Further studies are required to evaluate the role of PV treatments in the prevention of cerebrovascular disease.
Publisher
Walter de Gruyter GmbH
Subject
General Neuroscience
Reference48 articles.
1. Abdel-Rahman, I. and Murphy, C. (2015). Recurrent ischaemic stroke unveils polycythaemia vera. BMJ Case Rep. 9: bcr2014207625, https://doi.org/10.1136/bcr-2014-207625. 2. Arya, Y., Syal, A., Gupta, M., and Gaba, S. (2021). Advances in the treatment of polycythemia vera: trends in disease management. Cureus 30: e14193. 3. Barbui, T., Carobbio, A., Ghirardi, A., Masciulli, A., Rambaldi, A., and Vannucchi, A.M. (2017). No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on low-dose aspirin in polycythemia vera and cytoreductive therapy in polycythemia vera clinical trials. Haematologica 102: e219–e221, https://doi.org/10.3324/haematol.2017.165126. 4. Barbui, T., Carobbio, A., Finazzi, G., Vannucchi, A.M., Barosi, G., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Salmoiraghi, S., Zilio, P., et al.. (2011). Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96: 315–318, https://doi.org/10.3324/haematol.2010.031070. 5. Barosi, G., Mesa, R., Finazzi, G., Harrison, C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Vannucchi, A.M., Besses, C., et al.. (2013). Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121: 4778–4781, https://doi.org/10.1182/blood-2013-01-478891.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|